Хайлтын үр дүнгүүд - Giuseppe Cabibbo
- 43-н 1 - 20 үр дүнгүүдийг харуулж байна
- Дараагийн хуудас руу очих
-
1
-
2
-
3
-
4
-
5
-
6
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis -н Matteo Tacelli, Ciro Celsa, Bianca Magro, Luca Barresi, Salvatore Guastella, Gabriele Capurso, Luca Frulloni, Giuseppe Cabibbo, Calogero Cammà
Хэвлэсэн 2018Revisão -
7
-
8
Meta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn's Disease -н Sara Renna, Calogero Cammà, Irene Modesto, Giuseppe Cabibbo, Daniela Scimeca, Giuseppe Civitavecchia, Filippo Mocciaro, Ambrogio Orlando, Marco Enea, Mario Cottone
Хэвлэсэн 2008Revisão -
9
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C -н Fabio Salvatore Macaluso, Marcello Maida, Calogero Cammà, Giuseppe Cabibbo, Daniela Cabibi, Rossella Alduino, V. Di Marco, Antonio Craxı̀, Salvatore Petta
Хэвлэсэн 2014Artigo -
10
-
11
Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review -н Rodolfo Sacco, Gherardo Tapete, Natalia Simonetti, Rossella Sellitri, Veronica Natali, Sara Melissari, Giuseppe Cabibbo, Lilia Biscaglia, G. Bresci, Luca Giacomelli
Хэвлэсэн 2017Revisão -
12
-
13
-
14
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib -н Massimo Iavarone, Giuseppe Cabibbo, Marco Biolato, C. Della Corte, Marcello Maida, Marco Barbàra, Michele Basso, S. Vavassori, Antonio Craxı̀, Antonio Grieco, Carlo Cammà, Massimo Colombo
Хэвлэсэн 2015Artigo -
15
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems -н Calogero Cammà, V. Di Marco, Giuseppe Cabibbo, F Latteri, Luigi Sandonato, P. Parisi, Marco Enea, Massimo Attanasio, Massimo Galia, Nicola Alessi, Anna Licata, M Latteri, Antonio Craxı̀
Хэвлэсэн 2008Artigo -
16
Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma? -н Massimo Galia, Adele Taibbi, Daniele Marin, Alessandro Furlan, Marco Dioguardi Burgio, Francesco Agnello, Giuseppe Cabibbo, Bernard E. Van Beers, Tommaso Vincenzo Bartolotta, Massimo Midiri, Roberto Lagalla, Giuseppe Brancatelli
Хэвлэсэн 2014Artigo -
17
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension -н V. Di Marco, Vincenza Calvaruso, Donatella Ferraro, Maria Grazia Bavetta, Giuseppe Cabibbo, E. Conte, Calogero Cammà, Stefania Grimaudo, Rosaria Maria Pipitone, F. Simone, Sergio Peralta, Andrea Arini, Antonio Craxı̀
Хэвлэсэн 2016Artigo -
18
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus‐related cirrhosis who attained sustained virological response -н Savino Bruno, V. Di Marco, Massimo Iavarone, Luigi Roffi, V. Boccaccio, Andrea Crosignani, Giuseppe Cabibbo, Sonia Rossi, Vincenza Calvaruso, Alessio Aghemo, Luca Giacomelli, Antonio Craxı̀, Massimo Colombo, Patrick Maisonneuve
Хэвлэсэн 2017Artigo -
19
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? -н Giorgia Marisi, Alessandro Cucchetti, Paola Ulivi, Matteo Canale, Giuseppe Cabibbo, Leonardo Solaini, Francesco Giuseppe Foschi, Serena De Matteis, Giorgio Ercolani, Martina Valgiusti, Giovanni Luca Frassineti, Mario Scartozzi, Andrea Casadei‐Gardini
Хэвлэсэн 2018Revisão -
20
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis -н Amit G. Singal, Emily Zhang, Manasa Narasimman, Nicole E. Rich, Akbar K. Waljee, Yujin Hoshida, Ju Dong Yang, María Reig, Giuseppe Cabibbo, Pierre Nahon, Neehar D. Parikh, Jorge A. Marrero
Хэвлэсэн 2022Revisão
Хайх хэрэгслүүд:
Холбогдох сэдвүүд
Internal medicine
Medicine
Hepatocellular carcinoma
Gastroenterology
Oncology
Liver cancer
Biology
Cancer
Cirrhosis
Sorafenib
Confidence interval
Paleontology
Stage (stratigraphy)
Disease
Immunology
Proportional hazards model
Atezolizumab
Chemotherapy
Cohort
Hazard ratio
Immunotherapy
Liver disease
Virus
Bevacizumab
Carcinoma
Clinical trial
Lenvatinib
Meta-analysis
Nivolumab
Virology